Cronos Group Inc. Common Share (CRON)
CRON trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1656472/000165647226000016/0001656472-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRON on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001656472 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | BC |
| Canadian listing | TSX: CRON |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $146.6M |
| Net income | -$9.4M |
| Operating income | -$17.4M |
| Net margin | -6.4% |
| Operating margin | -11.9% |
| Revenue growth | +24.6% |
| Cash | $791.8M |
| Total assets | $1.2B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $411.2M cash; operating cash flow $20.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 366,471,299 (2026-11-02); 382,893,267 a year earlier; 381,113,564 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Davidson & Company LLP, Vancouver, Canada | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $63.5M | $13.8M | $34.3M | $411.2M | No debt tags | $206.2M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $53.0M | $32.1M | $24.0M | $467.0M | No debt tags | $179.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $45.2M | $13.8M | $10.9M | $821.9M | No debt tags | $159.5M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $44.5M | -$1.8M | $11.8M | $791.8M | No debt tags | $146.6M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $36.3M | $26.0M | $13.3M | $784.2M | No debt tags | $132.4M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $33.5M | -$39.7M | $2.8M | $794.4M | No debt tags | $130.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $32.3M | $6.1M | -$2.1M | $797.8M | No debt tags | $124.6M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $30.3M | $43.7M | $7.7M | $858.8M | No debt tags | $117.6M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 502 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.4% |
| 1 month | +5.6% |
| 3 months | +7.0% |
| Year to date | +28.5% |
| 1 year | +36.3% |
| From 52-week high | -9.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier